0 Items £0.00


This week, researchers revealed exciting results from the GCIG INTERLACE clinical trial, showing that a new way of using existing cancer drugs could mean more effective treatment options for cervical cancer. 

Today the Scottish Medicines Consortium (SMC) has approved the use of a new drug, pembrolizumab (Keytruda), on the NHS to treat some patients with advanced cervical cancer.